Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
JPI-547 with Bevacizumab in relapsed ovarian cancer
NCT07370818Phase 2Not yet recruiting
- Sponsor
- Onconic Therapeutics Inc.
- Start
- Feb 2026
- Primary completion
- Dec 2029
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of nesuparib in ovarian cancer, fallopian tube cancer (PFTC), primary peritoneal cancer (PPC), sponsored by Onconic Therapeutics Inc.. Planned start Feb 2026; status: not yet recruiting.
02
Drugs
nesuparib
03
Conditions
ovarian cancerfallopian tube cancer (PFTC)primary peritoneal cancer (PPC)
Beyond the preview
Go deeper on NCT07370818.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07370818.